MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

NCT ID: NCT05285553

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-25

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multicenter, parallel-group, controlled, double-masked (subject and investigator), randomized clinical trial with a total duration of four years.

Part 1 of this study will study the effectiveness of MiSight 1 Day in slowing myopia progression over three years in a US population. Subjects in Part 1 will wear MiSight 1 Day lenses or Proclear 1 day lenses.

Part 2 will study the stability of the effectiveness result over a one-year post-treatment period. All subjects in Part 2 will wear Proclear 1 day lenses. Subjects and investigators will remain masked from Part 1.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MiSight 1 day

MiSight 1 day

Group Type EXPERIMENTAL

MiSight 1 Day

Intervention Type DEVICE

Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.

Proclear 1 day

Proclear 1 day

Group Type ACTIVE_COMPARATOR

Proclear 1 day

Intervention Type DEVICE

Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.

Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MiSight 1 Day

Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.

Intervention Type DEVICE

Proclear 1 day

Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.

Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed Consent and Assent have been completed
2. Be between 8 and 12 years of age inclusive at the time of enrollment.
3. Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye
4. Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
5. Anisometropia: ≤ 1.50D SERE.
6. Astigmatism: ≤ 0.75 D
7. Free of ocular disease or abnormalities (including any corneal scar)
8. Currently have good general health.
9. Agree to accept the lens as assigned by the randomization.
10. Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol.
11. Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes.
12. Able to maintain the visit schedule.
13. Willingness to participate in the trial for 4 years.
14. Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
15. Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

Exclusion Criteria

1. Current or prior use of any pharmaceuticals or other methods for control of myopia, such as bifocals, progressive addition lenses, orthokeratology, atropine, pirenzepine or any other myopia control treatment.
2. Use of any systemic or topical ocular medications or over-the-counter artificial tears which might interfere with contact lens wear, pupil size, accommodation or refractive state, or require the lenses to be removed during the day.
3. Previously worn or currently wears rigid gas permeable contact lenses, including orthokeratology lenses
4. Has any of the following specific contraindications to MiSight 1 Day lenses at Baseline Visit:

* Acute and subacute inflammation or infection of the anterior chamber of the eye.
* Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
* Severe insufficiency of lacrimal secretion (dry eyes).
* Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
* Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
* Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
* Any active corneal infection (bacterial, fungal, or viral).
* If eyes are red or irritated.
* The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
5. Has history of:

* Corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
* Giant papillary conjunctivitis
* Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses
* A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
* Corneal hypoesthesia (reduced corneal sensitivity)
6. Keratoconus or an irregular cornea.
7. Strabismus or amblyopia.
8. Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
Minimum Eligible Age

8 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Gleason, OD

Role: PRINCIPAL_INVESTIGATOR

Foresight Regulatory Strategies, Inc. (FRS)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama School of Optometry

Birmingham, Alabama, United States

Site Status RECRUITING

Marshall B. Ketchum University Southern California College of Optometry

Fullerton, California, United States

Site Status RECRUITING

Vision Solutions Optometry Inc

La Mesa, California, United States

Site Status RECRUITING

Paje Optometric

Santa Ana, California, United States

Site Status RECRUITING

Coan Eye Care and Optical Boutique

Ocoee, Florida, United States

Site Status RECRUITING

West Broward Eyecare Associates

Tamarac, Florida, United States

Site Status RECRUITING

Bright Eyes Family Vision Care

Tampa, Florida, United States

Site Status RECRUITING

SoLo Eye Care & Eyewear Gallery

Chicago, Illinois, United States

Site Status RECRUITING

Illinois College of Optometry

Chicago, Illinois, United States

Site Status RECRUITING

Chicago College of Optometry

Downers Grove, Illinois, United States

Site Status RECRUITING

Carillon Vision Care

Glenview, Illinois, United States

Site Status RECRUITING

Brain Vision Institute

Schaumburg, Illinois, United States

Site Status RECRUITING

Clinical Optics Research Lab at IU School of Optometry

Bloomington, Indiana, United States

Site Status RECRUITING

Kannarr Eye Care

Pittsburg, Kansas, United States

Site Status RECRUITING

New England College of Optometry

Boston, Massachusetts, United States

Site Status RECRUITING

Cornea and Contact Lens Institute

Edina, Minnesota, United States

Site Status RECRUITING

Vision Source EyeCare

Kansas City, Missouri, United States

Site Status RECRUITING

Athens Eye Care

Athens, Ohio, United States

Site Status RECRUITING

Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

ProCare Vision Center, Inc.

Granville, Ohio, United States

Site Status RECRUITING

Miamisburg Vision Care

Miamisburg, Ohio, United States

Site Status RECRUITING

Eye Care Professionals

Powell, Ohio, United States

Site Status RECRUITING

Southern College of Optometry

Memphis, Tennessee, United States

Site Status RECRUITING

Texas State Optical

Beaumont, Texas, United States

Site Status RECRUITING

University of Houston College of Optometry

Houston, Texas, United States

Site Status RECRUITING

Vision One Eyecare

Katy, Texas, United States

Site Status RECRUITING

Lone Star Vision

Plano, Texas, United States

Site Status RECRUITING

Utah Eye Centers

Ogden, Utah, United States

Site Status RECRUITING

Virginia Pediatric Eye Care

Chesapeake, Virginia, United States

Site Status RECRUITING

Factoria Eye Clinic

Bellevue, Washington, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kathryn Richdale, OD, PhD

Role: CONTACT

917-755-4548

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Natalie West, O.D.

Role: primary

Erin Tomiyama, O.D., Ph.D.

Role: primary

Jamie Peters, O.D.

Role: primary

Vanessa Grichine, O.D.

Role: primary

Roxanne Achong-Coan, O.D.

Role: primary

Brianna Rhue, O.D.

Role: primary

Nathan Bonilla-Warford, O.D.

Role: primary

Katarzyna Aleszczyk, O.D.

Role: primary

Yi Pang, OD, PhD

Role: primary

Vakishan Nadarajah, O.D.

Role: primary

Andrew Neukirch, O.D.

Role: primary

Ingryd Lorenzana, O.D.

Role: primary

Peter Kollbaum, O.D.

Role: primary

Shane Kannarr, O.D.

Role: primary

Anh Bui, O.D.

Role: primary

Zachary Holland, O.D.

Role: primary

Ryan Powell, O.D.

Role: primary

Shane Foster, O.D.

Role: primary

Jennifer Fogt, O.D.

Role: primary

Katherine Bickle, O.D.

Role: primary

Keith Basinger, O.D.

Role: primary

Jason Miller, O.D.

Role: primary

Morgan Ollinger, O.D.

Role: primary

Samir N Patel, O.D.

Role: primary

Eric Ritchey, O.D.

Role: primary

Lawrence Wong, O.D.

Role: primary

Paola Diaz, O.D.

Role: primary

Michael Bullard, M.D.

Role: primary

Stacy Martinson, O.D.

Role: primary

Caroline Kaufman, O.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAS001/BC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spectacle Lens Visual Acuity Assessments Study
NCT05650190 ACTIVE_NOT_RECRUITING NA
Changes in Eye Shape With Myopia Management Interventions
NCT06450132 ACTIVE_NOT_RECRUITING PHASE4
Myopia Control Spectacle Lens Cessation Study
NCT05893979 ACTIVE_NOT_RECRUITING NA
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 ACTIVE_NOT_RECRUITING NA
Myoslow Lens Study to Control Myopia in Children
NCT06553404 ACTIVE_NOT_RECRUITING PHASE4